Anti-nucleocapsid Antibody Response After Two Doses of CoronaVac® Among Healthcare Workers

Introduction: The Coronavirus disease-2019 (COVID-19) pandemic that started over two years ago has led to high mortality and morbidity. Vaccine studies have been initiated worldwide to end the pandemic, and the CoronaVac® vaccine was first administered to healthcare workers at high risk of COVID-19...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Mediterranean Journal of Infection, Microbes and Antimicrobials
المؤلفون الرئيسيون: Ayşin KILINÇ TOKER, Duygu ÇERÇİOĞLU ÖZDEMİR, Esma EREN, Ayşe TURUNÇ ÖZDEMİR, Azade KANAT, İlhami ÇELİK, İbrahim TOKER
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Infectious Diseases and Clinical Microbiology Specialty Society of Turkey 2022-05-01
الموضوعات:
الوصول للمادة أونلاين:http://mjima.org/text.php?&id=322
_version_ 1848651525363073024
author Ayşin KILINÇ TOKER
Duygu ÇERÇİOĞLU ÖZDEMİR
Esma EREN
Ayşe TURUNÇ ÖZDEMİR
Azade KANAT
İlhami ÇELİK
İbrahim TOKER
author_facet Ayşin KILINÇ TOKER
Duygu ÇERÇİOĞLU ÖZDEMİR
Esma EREN
Ayşe TURUNÇ ÖZDEMİR
Azade KANAT
İlhami ÇELİK
İbrahim TOKER
author_sort Ayşin KILINÇ TOKER
collection DOAJ
container_title Mediterranean Journal of Infection, Microbes and Antimicrobials
description Introduction: The Coronavirus disease-2019 (COVID-19) pandemic that started over two years ago has led to high mortality and morbidity. Vaccine studies have been initiated worldwide to end the pandemic, and the CoronaVac® vaccine was first administered to healthcare workers at high risk of COVID-19 in Turkey. In our study, we aimed to investigate serum antibody levels after vaccination. Materials and Methods: Volunteer healthcare workers without COVID-19 disease who received two doses of CoronaVac® vaccine 28 days apart and were at least 14 days after the last dose of vaccine were included in this study. Assessment of antibodies against Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) in blood samples from participants was performed using the Elecsys® anti-SARS-CoV-2 electrochemiluminescence immunoassay. Samples with a cut-off index (COI) (COI; signal sample/cut-off) <1.0 were considered negative; whereas samples with COI≥1.0 were deemed positive. Results: A total of 269 healthcare workers, 168 women (62.5%), were included in our study. The mean age of the participants was 37.7±8.6 (minimum-maximum: 21-62). Antibody levels were positive in 188 (69.9%) of the participants. The median antibody level was 9.2 COI (interquartile ranges=3-34.7). In terms of mean age, the mean age of participants with negative antibodies was higher with a statistically significant difference (p=0.001). The antibody positivity rate of women was higher than that of men (p<0.001). No statistically significant association was found between the time elapsed after vaccination, presence of comorbidities, development of post-vaccine side effects, and antibody levels. It was found that one or more side effects developed in 45.7% of the participants after vaccination. Conclusion: Our study showed that seropositivity developed significantly in healthcare workers after the CoronaVac® vaccine. It emphasizes the importance of maintaining infection prevention and control measures and administering the SARS-CoV-2 vaccine for healthcare workers at high risk.
format Article
id doaj-e4d05add35bd458da93a2020a64fcbf0
institution Directory of Open Access Journals
issn 2147-673X
language English
publishDate 2022-05-01
publisher Infectious Diseases and Clinical Microbiology Specialty Society of Turkey
record_format Article
spelling doaj-e4d05add35bd458da93a2020a64fcbf02025-11-03T00:37:07ZengInfectious Diseases and Clinical Microbiology Specialty Society of TurkeyMediterranean Journal of Infection, Microbes and Antimicrobials2147-673X2022-05-0111110.4274/mjima.galenos.2022.2021.24Anti-nucleocapsid Antibody Response After Two Doses of CoronaVac® Among Healthcare WorkersAyşin KILINÇ TOKER0https://orcid.org/0000-0002-6775-1234Duygu ÇERÇİOĞLU ÖZDEMİR1https://orcid.org/0000-0003-1792-515XEsma EREN2https://orcid.org/0000-0002-2712-9694Ayşe TURUNÇ ÖZDEMİR3https://orcid.org/0000-0002-0748-8593Azade KANAT4https://orcid.org/0000-0002-0748-8593İlhami ÇELİK5https://orcid.org/0000-0002-2604-3776İbrahim TOKER6https://orcid.org/0000-0002-5346-2116Kayseri City Hospital, Clinic of Infectious Disease and Clinical Microbiology, Kayseri, TurkeyKayseri City Hospital, Clinic of Infectious Disease and Clinical Microbiology, Kayseri, TurkeyKayseri City Hospital, Clinic of Infectious Disease and Clinical Microbiology, Kayseri, TurkeyKayseri City Hospital, Clinic of Infectious Disease and Clinical Microbiology, Kayseri, TurkeyKayseri City Hospital, Clinic of Infectious Disease and Clinical Microbiology, Kayseri, TurkeyKayseri City Hospital, Clinic of Infectious Disease and Clinical Microbiology, Kayseri, TurkeyKayseri City Hospital, Clinic of Emergency Medicine, Kayseri, TurkeyIntroduction: The Coronavirus disease-2019 (COVID-19) pandemic that started over two years ago has led to high mortality and morbidity. Vaccine studies have been initiated worldwide to end the pandemic, and the CoronaVac® vaccine was first administered to healthcare workers at high risk of COVID-19 in Turkey. In our study, we aimed to investigate serum antibody levels after vaccination. Materials and Methods: Volunteer healthcare workers without COVID-19 disease who received two doses of CoronaVac® vaccine 28 days apart and were at least 14 days after the last dose of vaccine were included in this study. Assessment of antibodies against Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) in blood samples from participants was performed using the Elecsys® anti-SARS-CoV-2 electrochemiluminescence immunoassay. Samples with a cut-off index (COI) (COI; signal sample/cut-off) <1.0 were considered negative; whereas samples with COI≥1.0 were deemed positive. Results: A total of 269 healthcare workers, 168 women (62.5%), were included in our study. The mean age of the participants was 37.7±8.6 (minimum-maximum: 21-62). Antibody levels were positive in 188 (69.9%) of the participants. The median antibody level was 9.2 COI (interquartile ranges=3-34.7). In terms of mean age, the mean age of participants with negative antibodies was higher with a statistically significant difference (p=0.001). The antibody positivity rate of women was higher than that of men (p<0.001). No statistically significant association was found between the time elapsed after vaccination, presence of comorbidities, development of post-vaccine side effects, and antibody levels. It was found that one or more side effects developed in 45.7% of the participants after vaccination. Conclusion: Our study showed that seropositivity developed significantly in healthcare workers after the CoronaVac® vaccine. It emphasizes the importance of maintaining infection prevention and control measures and administering the SARS-CoV-2 vaccine for healthcare workers at high risk.http://mjima.org/text.php?&id=322covid-19sars-cov-2 antibodyvaccineside effect
spellingShingle Ayşin KILINÇ TOKER
Duygu ÇERÇİOĞLU ÖZDEMİR
Esma EREN
Ayşe TURUNÇ ÖZDEMİR
Azade KANAT
İlhami ÇELİK
İbrahim TOKER
Anti-nucleocapsid Antibody Response After Two Doses of CoronaVac® Among Healthcare Workers
covid-19
sars-cov-2 antibody
vaccine
side effect
title Anti-nucleocapsid Antibody Response After Two Doses of CoronaVac® Among Healthcare Workers
title_full Anti-nucleocapsid Antibody Response After Two Doses of CoronaVac® Among Healthcare Workers
title_fullStr Anti-nucleocapsid Antibody Response After Two Doses of CoronaVac® Among Healthcare Workers
title_full_unstemmed Anti-nucleocapsid Antibody Response After Two Doses of CoronaVac® Among Healthcare Workers
title_short Anti-nucleocapsid Antibody Response After Two Doses of CoronaVac® Among Healthcare Workers
title_sort anti nucleocapsid antibody response after two doses of coronavac r among healthcare workers
topic covid-19
sars-cov-2 antibody
vaccine
side effect
url http://mjima.org/text.php?&id=322
work_keys_str_mv AT aysinkilinctoker antinucleocapsidantibodyresponseaftertwodosesofcoronavacamonghealthcareworkers
AT duygucerciogluozdemir antinucleocapsidantibodyresponseaftertwodosesofcoronavacamonghealthcareworkers
AT esmaeren antinucleocapsidantibodyresponseaftertwodosesofcoronavacamonghealthcareworkers
AT ayseturuncozdemir antinucleocapsidantibodyresponseaftertwodosesofcoronavacamonghealthcareworkers
AT azadekanat antinucleocapsidantibodyresponseaftertwodosesofcoronavacamonghealthcareworkers
AT ilhamicelik antinucleocapsidantibodyresponseaftertwodosesofcoronavacamonghealthcareworkers
AT ibrahimtoker antinucleocapsidantibodyresponseaftertwodosesofcoronavacamonghealthcareworkers